Natural signaling blocker identified
Nature Immunology
November 8, 2010
Identification of a molecule that can halt immune cell signaling through the surface receptor gp130 is reported in this week’s online edition of Nature Immunology.
Certain mediators of inflammation and heightened antibody responses signal via gp130-linked receptors, marking these pathways as potential targets for therapeutic intervention in some autoimmune or inflammatory conditions, such as rheumatoid arthritis or inflammatory bowel disease.
Chris Hunter and colleagues show that the protein subunit p28 of interleukin 27 binds to gp130, preventing other molecules from interacting with the receptor and thus blunts the ability of gp130 to transmit signals. As a proof-of-principle, they show mice transiently expressing p28 show less severe disease manifestation in an experimental autoimmune encephalomyelitis (EAE) model, which mimics aspects of the human disease multiple sclerosis.
doi: 10.1038/ni.1957
Research highlights
-
Aug 12
Ageing: Mutations in the ageing human heart identifiedNature Aging
-
Aug 12
Palaeontology: T. rex and relatives traded big eyes for bigger bitesCommunications Biology
-
Aug 10
Epidemiology: Estimating the risk of SARS-related coronaviruses from bats in Southeast AsiaNature Communications
-
Aug 5
Microbiology: Single switch makes Escherichia coli beneficial insect partnerNature Microbiology
-
Aug 5
Conservation: More than half of unassessable species may be at risk of extinctionCommunications Biology
-
Aug 4
Physiology: Restoring cellular functions in pigs after deathNature